Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04336410
Previous Study | Return to List | Next Study

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04336410
Recruitment Status : Recruiting
First Posted : April 7, 2020
Last Update Posted : June 5, 2020
Sponsor:
Collaborator:
Coalition for Epidemic Preparedness Innovations (CEPI)
Information provided by (Responsible Party):
Inovio Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE April 3, 2020
First Posted Date  ICMJE April 7, 2020
Last Update Posted Date June 5, 2020
Actual Study Start Date  ICMJE April 3, 2020
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 21, 2020)
  • Percentage of Participants with Adverse Events (AEs) [ Time Frame: Baseline up to Week 52 ]
  • Percentage of Participants with Administration (Injection) Site Reactions [ Time Frame: Day 0 up to Week 52 ]
  • Percentage of Participants with Adverse Events of Special Interest (AESIs) [ Time Frame: Baseline up to Week 52 ]
  • Change from Baseline in Antigen-Specific Binding Antibody Titers [ Time Frame: Baseline up to Week 52 ]
  • Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response [ Time Frame: Baseline up to Week 52 ]
Original Primary Outcome Measures  ICMJE
 (submitted: April 3, 2020)
  • Percentage of Participants with Adverse Events (AEs) [ Time Frame: Baseline up to Week 28 ]
  • Percentage of Participants with Administration (Injection) Site Reactions [ Time Frame: Day 0 up to Week 28 ]
  • Percentage of Participants with Adverse Events of Special Interest (AESIs) [ Time Frame: Baseline up to Week 28 ]
  • Change from Baseline in Antigen-Specific Binding Antibody Titers [ Time Frame: Baseline up to Week 28 ]
  • Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response [ Time Frame: Baseline up to Week 28 ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Official Title  ICMJE Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers
Brief Summary This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Coronavirus Infection
Intervention  ICMJE
  • Drug: INO-4800
    INO-4800 will be administered ID on Day 0 and Week 4.
  • Device: CELLECTRA® 2000
    EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Week 4.
Study Arms  ICMJE
  • Experimental: Group 1: INO-4800
    Participants will receive one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
    Interventions:
    • Drug: INO-4800
    • Device: CELLECTRA® 2000
  • Experimental: Group 2: INO-4800
    Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
    Interventions:
    • Drug: INO-4800
    • Device: CELLECTRA® 2000
  • Experimental: Group 3: INO-4800
    Participants will receive one ID injection of 0.5 mg of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
    Interventions:
    • Drug: INO-4800
    • Device: CELLECTRA® 2000
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 3, 2020)
120
Original Estimated Enrollment  ICMJE
 (submitted: April 3, 2020)
40
Estimated Study Completion Date  ICMJE July 2021
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Judged to be healthy by the Investigator on the basis of medical history, physical examination and vital signs performed at screening.
  • Able and willing to comply with all study procedures.
  • Screening laboratory results within normal limits or deemed not clinically significant by the Investigator.
  • Body Mass Index of 18-30 kg/m^2, inclusive, at screening.
  • Negative serological tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human Immunodeficiency Virus (HIV) antibody at screening.
  • Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically significant findings (e.g. Wolff-Parkinson-White syndrome).
  • Use of medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until 3 months following last dose, be post-menopausal, be surgically sterile or have a partner who is sterile.

Exclusion Criteria:

  • Pregnant or breastfeeding or intending to become pregnant or father children within the projected duration of the trial from screening until 3 months following last dose.
  • Is currently participating in or has participated in a study with an investigational product within 30 days preceding Day 0.
  • Previous exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or receipt of an investigational product for the prevention or treatment of COVID-19, middle east respiratory syndrome (MERS), or severe acute respiratory syndrome (SARS).
  • In a current occupation with high risk of exposure to SARS-CoV-2 (e.g., health care workers or emergency response personnel having direct interactions with or providing direct care to patients).
  • Current or history of the following medical conditions:

    • Respiratory diseases
    • Hypersensitivity or severe allergic reactions to vaccines or drugs
    • Diagnosis of diabetes mellitus
    • Hypertension
    • Malignancy within 5 years of screening
    • Cardiovascular diseases
  • Immunosuppression as a result of underlying illness or treatment including:

    • Primary immunodeficiencies
    • Long term use (≥7 days) of oral or parenteral glucocorticoids
    • Current or anticipated use of disease-modifying doses of anti-rheumatic drugs and biologic disease-modifying drugs
    • History of solid organ or bone marrow transplantation
    • Prior history of other clinically significant immunosuppressive or clinically diagnosed autoimmune disease
  • Fewer than two acceptable sites available for intradermal (ID) injection and electroporation (EP) considering the deltoid and anterolateral quadriceps muscles.
  • Reported smoking, vaping, or active drug, alcohol or substance abuse or dependence.
  • Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Inovio Call Center (267) 440-4237 clinical.trials@inovio.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04336410
Other Study ID Numbers  ICMJE COVID19-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.
Supporting Materials: Study Protocol
Supporting Materials: Informed Consent Form (ICF)
Time Frame: Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.
Access Criteria: Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.
Responsible Party Inovio Pharmaceuticals
Study Sponsor  ICMJE Inovio Pharmaceuticals
Collaborators  ICMJE Coalition for Epidemic Preparedness Innovations (CEPI)
Investigators  ICMJE
Study Director: ShuPing Yang, MD, PhD Inovio Pharmaceuticals
PRS Account Inovio Pharmaceuticals
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP